Multicenter, Randomized, Open Label, Parallel Group Study to Evaluate the Safety and Efficacy of Orsiro Hybrid Drug Eluting Stent
Phase of Trial: Phase IV
Latest Information Update: 22 Apr 2016
Price : $35 *
At a glance
- Drugs Sirolimus (Primary) ; Zotarolimus
- Indications Angina pectoris; Coronary artery disease; Myocardial infarction
- Focus Therapeutic Use
- Acronyms ORIENT
- 19 Apr 2016 Status changed from recruiting to completed.
- 02 May 2013 Planned number of patients changed from 345 to 375 as reported by ClinicalTrials.gov.
- 17 Apr 2013 New trial record